Recent 8-K filings for EVMN

• August 6, 2026, 4:06 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Evommune Q2 net loss $32.2M; EVO756 AD Phase 2b data due Sept 2026

  Net loss of $32.2M for Q2 2026 vs $13.6M in Q2 2025; cash $288M as of June 30, 2026.

• July 30, 2026, 8:01 AM ET other material materiality 0.55 neutral item 7.01item 9.01

  Evommune doses first patient in Phase 2b trial of EVO756 for migraine prophylaxis

  First patient dosed in Phase 2b trial of MRGPRX2 inhibitor EVO756 for migraine prophylaxis.

• June 29, 2026, 8:32 AM ET other material materiality 0.80 negative item 7.01item 8.01item 9.01

  Evommune EVO756 Phase 2b misses primary endpoint in CSU; development halted for that indication

  Phase 2b trial of EVO756 in 160 CSU patients did not meet primary endpoint of UAS7 change at 12 weeks at any dose.

• June 2, 2026, 4:07 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  Evommune stockholders elect Peña and Bauer as directors, ratify BDO auditor

  Luis Peña elected with 21,859,596 votes for, 1,949,148 withheld, and 885,750 broker non-votes.

• May 7, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Evommune reports Q1 net loss $21.7M; EVO756 Phase 2b data due June 2026 in CSU

  Net loss $21.7M in Q1 2026 vs $14.6M prior year; cash, equivalents and investments $307.0M as of March 31, 2026.

• April 13, 2026, 7:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  Evommune hosts webcast on MRGPRX2 inhibition for migraine treatment

  Presentation reviews migraine treatment landscape and potential role of MRGPRX2 inhibition.

• March 5, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Evommune reports Q4/FY2025 net loss $28.3M/$68.9M; positive EVO301 Ph2a data; $125M raise

  Q4 net loss $28.3M; FY net loss $68.9M vs $66.8M prior year. Revenue $13.0M FY (Maruho deal). Cash $216.7M at Dec 31, 2025.

• February 13, 2026, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements ×2◈ Equity Issuances

  Evommune announces $125M private placement of 4.5M shares at $27.88/share

  Gross proceeds ~$125M from sale of 4,494,279 shares at $27.88 per share to institutional investors.

• February 10, 2026, 6:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Evommune reports positive Phase 2a top-line data for EVO301 in atopic dermatitis

  Primary endpoint met: 99.8% of posterior distribution exceeded 8% improvement threshold vs placebo.

• December 11, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Evommune reports Q3 2025 net loss $12.5M; IPO raised $172.5M, three Phase 2 readouts due in 2026

  Completed IPO in Nov 2025 of 10.78M shares at $16.00, raising $172.5M gross proceeds.

• November 7, 2025, 6:59 PM ET other material materiality 0.30 neutral item 5.03item 9.01 ◈ Governance Changes ×2

  Evommune amends charter and bylaws upon IPO closing on Nov 7, 2025

  Filed amended and restated certificate of incorporation with Delaware Secretary of State on November 7, 2025.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event other_material

2 positive 2 negative 7 neutral

source · EVMN on sec.gov